Published: November 19, 2013. Johnson & Johnson and lawyers for patients injured by a flawed hip implant announced a multibillion-dollar deal on Tuesday to settle thousands of lawsuits, but it was not clear whether the deal would satisfy enough claimants.
Johnson & Johnson has tentatively agreed to a settlement that could reach up to $4 billion to resolve thousands of lawsuits filed by patients injured by a flawed all-metal replacement hip, said two lawyers briefed on the plan.
Both Johnson & Johnson's (NYSE: JNJ ) Biosense-Webster and St. Jude Medical (NYSE: STJ ) are making key investments in products like cardiac mapping to win market share in this growing electrophysiology market.
Johnson & Johnson may pay as much as $1 billion to insurers who covered the medical costs of removing its recalled hip implants under a settlement announced last week, according to a lawyer involved in the accord.
Federal regulators approved a new drug from Johnson & Johnson for use in treating chronic hepatitis C infections. The Food and Drug Administration said it had approved the drug, a protease inhibitor that blocks a protein needed by the virus to replicate.
A new class of oral drugs for curing hepatits C is hitting the markets this winter, displacing injectible predecessors and ushering in treatments that are shorter and in some cases avoid side-affect riddled interferon.
Although I will focus on Johnson & Johnson in this discussion, the strategy here applies to many companies that have a solid history of increasing (or at least not cutting) their dividends over time, even during recessions.